Showing results (81-90 of 96) with videos related to
Sort By:
Pageof 10
Mutation Research|May 12, 1997
MeIQx-DNA adduct formation in rodent and human tissues at low dosesK W Turteltaub, R J Mauthe, K H Dingley, et al.Journal of Pharmaceutical and Biomedical Analysis|December 29, 2000
A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extractsR C Garner, J Barker, C Flavell, et al.IARC Scientific Publications|January 1, 1984
An enzyme-linked immunosorbent procedure for assaying aflatoxin B1C N Martin, R C Garner, F Tursi, et al.Carcinogenesis|May 1, 1985
6-Nitrochrysene is a potent tumorigen in newborn miceW F Busby, R C Garner, F L Chow, et al.International Journal of Cancer|February 6, 1999
Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low doseR J Mauthe, K H Dingley, S H Leveson, et al.Chemical Research in Toxicology|April 17, 1998
Metabolism of the food-borne mutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in humansR J Turesky, R C Garner, D H Welti, et al.Investigational New Drugs|March 10, 2007
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometryJ H Beumer, R C Garner, M B Cohen, et al.Cancer Letters|September 30, 1999
Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low dosesK W Turteltaub, K H Dingley, K D Curtis, et al.Carcinogenesis|February 14, 2003
Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancerJ H Barrett, G Smith, R Waxman, et al.Clinical Pharmacology and Therapeutics|October 29, 2010
Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivoJ Chen, R C Garner, L S Lee, et al.Pageof 10